Evaluation of the effect of Iranian medicine product, Algro, on patients with coronavirus 19

ABSTRACT

ConditionCOVID-19.
U07.2 COVID-19, virus not identified, COVID-19;U07.2

InterventionIntervention 1 Intervention group The medicinal product includes a capsule composed of two herbs(salix ,lambs quarter). The amount of each of these substances in the capsule is 250 mg. The dosage of the product is three capsules a day, which is half an hour before each meal. This product is prepared by Armaghan Sabz Araz Teb Pharmaceutical Company.In this group, common medical drug is also consumed according to the latest protocol of the Ministry of Health. Intervention 2 Control group Patient in control group use common medicine based on the latest protocol of the Ministry of Health and placebo.

Primary outcome:Measurement of cough severity. Timepoint Day 1 before and at the end of treatment. Method of measurement Standard cough questionnaire.;Severity of shortness of breath. Timepoint Day 1 before and at the end of treatment. Method of measurement Shortness Of Breath With Daily Activity (SOBDA) Questionnaire.;Lung radiologic changes. Timepoint At beginning and end of the study. Method of measurement Chest CT scan.

CriteriaInclusion criteria Male or female patients 18 years old and older with COVID-19
positive coronavirus 19 PCR
Ground glass view at low-dose CT scan
Arterial oxygen saturation less than 93%
Consciously completed consent form completed by the patient or the patient's supervisor

Exclusion criteria History of pulmonary malignancy
History of asthma or COPD
History of Disabling disease or malignancy
Liver or kidney disorders